Analyst Price Targets — CORT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 20, 2026 11:05 am | — | H.C. Wainwright | $67.00 | $34.24 | TheFly | Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright |
| January 23, 2026 11:49 am | — | Canaccord Genuity | $100.00 | $41.30 | TheFly | Corcept Therapeutics price target raised to $100 from $99 at Canaccord |
| January 22, 2026 5:41 pm | Swayampakula Ramakanth | H.C. Wainwright | $105.00 | $41.47 | TheFly | Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright |
| January 2, 2026 11:34 am | Swayampakula Ramakanth | H.C. Wainwright | $90.00 | $36.35 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright |
| January 2, 2026 11:22 am | Edward Nash | Canaccord Genuity | $99.00 | $36.90 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity |
| December 31, 2025 6:05 pm | — | Truist Financial | $50.00 | $34.25 | TheFly | Corcept Therapeutics price target lowered to $50 from $135 at Truist |
| December 31, 2025 2:50 pm | — | Wolfe Research | $30.00 | $33.12 | TheFly | Corcept downgraded to Underperform at Wolfe after CRL for relacorilant |
| December 16, 2025 10:11 am | Ashwani Verma | UBS | $95.00 | $87.30 | TheFly | Corcept Therapeutics initiated with a Neutral at UBS |
| September 10, 2025 12:28 pm | — | Canaccord Genuity | $140.00 | $71.62 | TheFly | Corcept Therapeutics price target raised to $140 from $137 at Canaccord |
| May 6, 2025 1:57 pm | Joon Lee | Truist Financial | $135.00 | $70.74 | TheFly | Corcept Therapeutics price target lowered to $135 from $150 at Truist |
Latest News for CORT
SAN FRANCISCO, April 18, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm urges investors who suffered significant losses between October 31, 2024, and December 30, 2025 (the "Class Period"), to submit their losses now.
SAN FRANCISCO , April 18, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm urges investors who suffered significant losses between October 31, 2024, and December 30, 2025 (the "Class Period"), to submit their losses…
New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline. SO WHAT: If you purchased Corcept common stock during the Class Period you may be…
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), of the important April 21, 2026 lead plaintiff deadline.
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CORT.
U.S. House Trading
No House trades found for CORT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.